Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value at other companies

Merck & Co. logo
Merck & Co.MRK
——
Replimune Group logo
Replimune GroupREPL
——
Neuropace, Inc. logo
Neuropace, Inc.NPCE
——

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value?
Relmada Therapeutics, Inc. (RLMD) reported share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value of $16.2M in Q1 2026.
What is the long-term trend for Relmada Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value?
Over 2 years (2021 to 2023), Relmada Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value has grown at a -77.2% compound annual growth rate (CAGR), from $19.51M to $1.02M.